SCHEMBL25027697

SCHEMBL25027697

Nc1cc(F)c(O)c(F)c1Cl

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.36
HSD17B10 Q99714 4/20 0.33
HPGD P15428 3/20 0.33
TSHR P16473 2/20 0.33
CASP1 P29466 1/20 0.33
ESR1 P03372 1/20 0.33
ESR2 Q92731 1/20 0.33
CYP3A4 P08684 1/20 0.32
MAPK1 P28482 2/20 0.32
ALDH1A1 P00352 2/20 0.32
ALOX15 P16050 2/20 0.32
ALOX12 P18054 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
CA12 O43570 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA7 P43166 1/20 0.32
CA9 Q16790 1/20 0.32
CA14 Q9ULX7 1/20 0.32
VRK1 Q99986 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30008043 1.00 THRB (0.36) THRBHSD17B10HPGDTSHRCASP1
SCHEMBL25027710 0.82 THRB (0.46) THRBHSD17B10HPGDTSHRCASP1
SCHEMBL22831784 0.82 THRB (0.36) THRBHSD17B10HPGDTSHRCASP1
SCHEMBL31150392 0.82 THRB (0.36) THRBHSD17B10HPGDTSHRCASP1
SCHEMBL25027714 0.78 ERN1 (0.37) THRBHSD17B10HPGDTSHRCASP1
SCHEMBL3790406 0.78 VRK1 (0.34) ALDH1A1VRK1GAA
SCHEMBL9153454 0.78 GRIN2D (0.36) CYP3A4ALDH1A1GAA
SCHEMBL8525834 0.78 GAA (0.35) CYP3A4ALDH1A1CA12CA1CA2
SCHEMBL25038844 0.75 GAA (0.32) THRBCYP3A4MAPK1ALDH1A1GAA
SCHEMBL24133307 0.74 HSD17B10 (0.35) HSD17B10HPGDTSHRCASP1ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115215799-B Urea multi-target tyrosine kinase inhibitor and multiple medical applications thereof 上海爱博医药科技有限公司 2024-05-31 CN disclosed
US-11912663-B2 Multi-targeted tyrosine kinase inhibitors and their pharmaceutical uses SHANGHAI AB PHARMATECH LTD. (CN) 2024-02-27 US disclosed
US-11912663-B2 Multi-targeted tyrosine kinase inhibitors and their pharmaceutical uses SHANGHAI AB PHARMATECH LTD. (CN) 2024-02-27 US disclosed
US-20230124784-A1 MULTI-TARGETED TYROSINE KINASE INHIBITORS AND THEIR PHARMACEUTICAL USES SHANGHAI AB PHARMATECH LTD. (CN) 2023-04-20 US disclosed
WO-2023016543-A1 UREA MULTI-TARGET TYROSINE KINASE INHIBITOR AND MULTIPLE MEDICAL APPLICATIONS THEREOF 上海爱博医药科技有限公司 2023-02-16 WO disclosed
WO-2023016540-A1 UREA MULTI-TARGET TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF 上海爱博医药科技有限公司 2023-02-16 WO disclosed
WO-2023016540-A1 UREA MULTI-TARGET TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF 上海爱博医药科技有限公司 2023-02-16 WO disclosed
WO-2023016543-A1 UREA MULTI-TARGET TYROSINE KINASE INHIBITOR AND MULTIPLE MEDICAL APPLICATIONS THEREOF 上海爱博医药科技有限公司 2023-02-16 WO disclosed
CN-115215799-A Urea multi-target tyrosine kinase inhibitor and various medical applications thereof 上海爱博医药科技有限公司 2022-10-21 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11912663-B2 Multi-targeted tyrosine kinase inhibitors and their pharmaceutical uses ABL1, ERBB2, RET THRB 510/4885HSD17B10 3716/4885HPGD 2798/4885
US-20230124784-A1 MULTI-TARGETED TYROSINE KINASE INHIBITORS AND THEIR PHARMACEUTICAL USES ABL1, ERBB2, RET THRB 510/4885HSD17B10 3716/4885HPGD 2798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.